The Scientific World Journal / 2014 / Article / Tab 2

Review Article

Efficacy and Safety of Acotiamide for the Treatment of Functional Dyspepsia: Systematic Review and Meta-Analysis

Table 2

Pooled RR of acotiamide versus placebo for elimination of FD symptoms by Mantel-Haenszel fixed-effect model.

Groups and subgroupsNumber of trials [reference]Number of patientsRR; 95% CI value Test of heterogeneity
value

PDS2 [16]3961.29; 1.09–1.530.0030.8300%
 50 mg, tid1 [16]1511.08; 0.76–1.530.660NANA
 100 mg, tid2 [16]2061.41; 1.07–1.850.0100.8600%
 300 mg, tid2 [16]2181.33; 1.01–1.750.0400.9600%
EPS2 [16]3200.92; 0.76–1.110.3900.9700%
 50 mg, tid1 [16]730.88; 0.58–1.340.550NANA
 100 mg, tid2 [16]1840.96; 0.72–1.290.8000.5200%
 300 mg, tid2 [16]1920.90; 0.67–1.210.4800.9900%
Postprandial fullnessa3 [16, 25]14381.90; 1.37–2.64<0.0010.03060%
 50 mg, tid1 [16]1493.19; 1.36–7.440.007NANA
 100 mg, tid3 [16, 25]11901.75; 1.14–2.660.0100.06064%
 300 mg, tid2 [16]3372.05; 0.79–5.340.1400.04077%
Upper abdominal bloating3 [16, 25]12321.30; 1.12–1.50<0.0010.9300%
 50 mg, tid1 [16]1351.26; 0.79–2.010.330NANA
 100 mg, tid3 [16, 25]10011.29; 1.08–1.540.0050.5500%
 300 mg, tid2 [16]3101.34; 0.99–1.800.0600.7300%
Early satiety3 [16, 25]12061.39; 1.19–1.61<0.0010.8300%
 50 mg, tid1 [16]1331.60; 0.95–2.700.080NANA
 100 mg, tid3 [16, 25]10021.39; 1.16–1.67<0.0010.4500%
 300 mg, tid2 [16]2851.29; 0.94–1.760.1100.8300%

aMantel-Haenszel random-effects model.
CI, confidential interval; FD, functional dyspepsia; NA, not applicable; RR, risk ratio; and tid, three times daily.